Corbus Pharmaceuticals Holdings, Inc.
CRBPAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 26, 2026 | H.C. Wainwright | $35.00(+209%) | $11.31 | StreetInsider | |
| Aug 13, 2026 | Mizuho Securities | Graig Suvannavejh | $33.00(+238%) | $9.76 | StreetInsider |
| May 22, 2026 | Mizuho Securities | Graig Suvannavejh | $44.00(+259%) | $12.27 | TheFly |
| May 12, 2026 | Jefferies | Maury Raycroft | $33.00(+189%) | $11.43 | TheFly |
| Oct 29, 2025 | Mizuho Securities | $39.00(+128%) | $17.12 | TheFly | |
| Oct 20, 2025 | Piper Sandler | $51.00(+202%) | $16.86 | TheFly | |
| Oct 20, 2025 | H.C. Wainwright | $40.00(+107%) | $19.32 | StreetInsider | |
| Dec 2, 2024 | Piper Sandler | Biren Amin | $35.00(+96%) | $17.82 | StreetInsider |
| Oct 21, 2024 | Oppenheimer | Jeff Jones | $60.00(+226%) | $18.41 | StreetInsider |
| Sep 20, 2024 | B.Riley Financial | Kalpit Patel | $40.00(+105%) | $19.51 | StreetInsider |
| Sep 13, 2024 | Mizuho Securities | Graig Suvannavejh | $74.00(+43%) | $51.58 | StreetInsider |
| Aug 7, 2024 | Oppenheimer | Jeff Jones | $88.00(+82%) | $48.30 | StreetInsider |
| Jul 22, 2024 | H.C. Wainwright | Andres Maldonado | $80.00(+38%) | $58.00 | TheFly |
| Jun 11, 2024 | RBC Capital | Brian Abrahams | $82.00(+87%) | $43.87 | StreetInsider |
| Jun 3, 2024 | Oppenheimer | Jeff Jones | $80.00(+87%) | $42.80 | StreetInsider |
| May 20, 2024 | RBC Capital | Brian Abrahams | $77.00(+71%) | $45.00 | StreetInsider |
| Mar 6, 2024 | Jefferies | Maury Raycroft | $46.00(+37%) | $33.58 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 14, 2026 |
| Oppenheimer | maintain | Outperform | Aug 7, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 7, 2026 |
| Mizuho | maintain | Outperform | Jun 23, 2026 |
| Oppenheimer | maintain | Outperform | Jun 17, 2026 |
| Wedbush | maintain | Outperform | May 27, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 26, 2026 |
| Mizuho | maintain | Outperform | May 22, 2026 |
| Jefferies | maintain | Buy | May 13, 2026 |
| Guggenheim | maintain | Buy | May 13, 2026 |
| Oppenheimer | maintain | Outperform | May 13, 2026 |
| Oppenheimer | maintain | Outperform | Mar 10, 2026 |
| RBC Capital | maintain | Outperform | Nov 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 20, 2025 |
| Wedbush | maintain | Outperform | Oct 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 17, 2025 |
| Oppenheimer | maintain | Outperform | Aug 6, 2025 |
| RBC Capital | maintain | Outperform | May 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 7, 2025 |
| Oppenheimer | maintain | Outperform | May 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 12, 2025 |
| Jefferies | maintain | Buy | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2025 |
| RBC Capital | maintain | Outperform | Aug 7, 2024 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-1.27| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-1.81 | $-1.26 | — | $1.1M |
| May 12, 2026 | $-1.23 | $-1.26 | — | — |
| Mar 9, 2026 | $-1.25 | $-1.78 | — | $1.7M |
| Nov 12, 2025 | $-1.90 | $-1.80 | — | $1.1M |
| Aug 5, 2025 | $-1.44 | $-1.55 | — | — |
| May 6, 2025 | $-1.39 | $-1.26 | — | — |
| Mar 11, 2025 | $-0.78 | $-1.02 | — | — |
| Nov 7, 2024 | $-1.15 | $-0.99 | — | — |
News
NORWOOD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month price
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase 1B study will be presented as a poster presentation at Obesity Week® 2026, taking place from November 14–17, 2026 in National Harbor, MD.
Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for treatment annually NORWOOD, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that the first patient has been dosed in i…
Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.
Corbus Pharmaceuticals NASDAQ: CRBP reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week, placebo-controlled study enrolled 254 patients across 15 U.S. sites, with participants having an average body mass index of approximately 37 and 71% of participants being female.
Clinical-stage biopharmaceutical firm Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) on Monday reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity treatment.
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile Data support CRB-913's potential to establish a new class of oral non-incretin obesity medicines Data selected for late-breaking presentation at ObesityWeek® 2026 Company will hold an investor call at 8:…
Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT
NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement equity awards outside of the Company's stockholder-approved equity compensation plans to Leonardo Nicacio in connection with his commencement of employment as Chief Medical Officer of the Company. The grants were approved by the Compensation Committee of the Board of Directors eff…